On Randomized News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from On randomized. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In On Randomized Today - Breaking & Trending Today

LUMC to Fund New Clinical Trial of Cynata's Cymerus MSCs in Kidney Transplantation

Key Highlights: Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidney transplant Trial to be funded by LUMC; Cynata will supply iPSC-derived Cymerus mesenchymal stem cells (MSCs) at its cost to facilitate the trial and has full commercial rights There are approximately 130,000 kidney transplants around the world each year. Kidney transplantation is life-saving in patients with chronic renal failure and frees the patient from the need for dialysis. Currently, lifelong immune suppressive therapy is required in renal transplant patients to reduce the risk of rejection. This can lead to increased risk of infections and cancer and the main anti-rejection drugs are also directly toxic to the kidneys In previous clinical trials, mesenchymal stromal/stem cells have shown potential to enable the early withdrawal of anti-rejection drugs in renal transplant recipients without increased rejection and wi ....

Cynata Cymerus Mscs , Ross Macdonald , Cymerus Mscs , Leiden University Medical Center , Head Of The Department Internal Medicine , Department Of Nephrology , Cynata Therapeutics Limited , Key Highlights , Mesenchymal Stromal Cell Therapy , Renal Transplant Recipients , Ton Rabelink , Internal Medicine , Chief Executive Officer , Professor Rabelink , Managing Director , Clinical Trial , Cynata Therapeutics , Therapeutics Limited , Key Highlights Cynata To Collaborate With Leiden University Medical Center Lumc In The Netherlands , Na New Clinical Trial In Patients Who Have Receiveda Kidney Transplant To Be Funded By Lumc Cynata Will Supply Ipsc Derived Cymerus Mesenchymal Stem Cells Mscs At Its Cost Facilitate The And Has Full Commercial Rights There Are Approximately 130 , 000 Kidney Transplants Around The World Each Year Transplantation Is Life Saving In Patients With Chronic Renal Failure And Frees Patient From Need For Dialysis Currently , Ifelong Immune Suppressive Therapy Is Required In Renal Transplant Patients To Reduce The Risk Of Rejection This Can Lead Increased Infections And Cancer Main Anti Drugs Are Also Directly Toxic Kidneys Previous Clinical Trials , Esenchymal Stromal Stem Cells Have Shown Potential To Enable The Early Withdrawal Of Anti Rejection Drugs In Renal Transplant Recipients Without Increased And With Preserved Function Melbourne , Nov 4 , 022 Prnewswire Cynata Therapeutics Limited Asx Quot Cyp Or , A Clinical Stage Biotechnology Company Specialising In Cell Therapeutics ,

Sirolimus Coated Balloon in BTK Treatment makes a bold presence at VEITH 2022 - Lights up NY Times Square, NASDAQ

Tampa (Florida) [US], December 3 (ANI/PRNewswire): VEITH 2022 witnessed a surge of supporting clinical data for Sirolimus Coated Balloon in the treatment of Below-the-Knee (BTK) disease. Concept Medical Inc. hosted a lunch symposium titled 'Sirolimus Coated Balloon in PAD Treatment: Choice of The Future' which explored the utility of Sirolimus Coated Balloon treatment in PAD. The session was chaired by Prof. Sahil Parikh, co-moderated by Prof. Edward Choke and Prof. Aloke Finn with interesting presentations by Prof. Ulf Teichgraber and Prof. Francesco Liistro. One of the highlights of the session was the follow up data of clinical outcomes of the XTOSI Trial. XTOSI (Xtreme Touch Sirolimus coated PTA balloon) is a single arm trial for Sirolimus Coated Balloon (MagicTouch PTA) investigating the clinical use and safety of the device in the treatment of infrainguinal Peripheral Arterial Disease (PAD). This prospective, premarket, non-randomized, all comers single-arm study, led by ....

New York , United States , Aloke Finn , Francesco Liistro , Ulf Teichgraber , Sahil Parikh , Concept Medical Inc , Sirolimus Coated Balloon , Edward Choke , Xtreme Touch Sirolimus , Peripheral Arterial Disease , Magic Touch , Coated Balloon , Sengkang General Hospital , Sirolimus Coated , New York Times Square , Tampa Florida Us , Ecember 3 Ani Prnewswire Veith 2022 Witnesseda Surge Of Supporting Clinical Data For Sirolimus Coated Balloon In The Treatment Below Knee Btk Disease Concept Medical Inc Hosteda Lunch Symposium Titled 39 Pad Choice Future Which Explored Utility Session Was Chaired By Prof Sahil Parikh , O Moderated By Prof Edward Choke And Aloke Finn With Interesting Presentations Ulf Teichgraber Francesco Liistro One Of The Highlights Session Was Follow Up Data Clinical Outcomes Xtosi Trial Xtreme Touch Sirolimus Coated Pta Balloon Isa Single Arm For Magictouch Investigating Use Safety Device In Treatment Infrainguinal Peripheral Arterial Disease Pad This Prospective , On Randomized , Ll Comers Single Arm Study , Ed By Pi Prof Edward Choke Enrolled 50 Patients To Study The Magic Touch Pta Sirolimus Coated Balloon Concept Medical Inc At Sengkang General Hospital , Ingapore It Is The World 39s First Trial Of Sirolimus Coated Balloon For Btk Disease And Has Longest Follow Up Data While Primary Endpoints Already Suggested Promising Patency Safety At 6 Months , He Data Presented At Veith 2022 Shed More Light On The Longer Term Efficacy And Safety Of Sirolimus Coated Balloon Prof Edward Choke , Urther Presented Updates On The Future Sfa And Btk Rcts , A Family Of Randomised Trials Set To Enrol 279 And 219 Patients Respectively ,